Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘Marseille Immunopole’

mimabs_logoOne of the partners of the Marseille Immunopôle cluster is an immuno-technology center focused on translational research called MI-mAbs (“MI” for Marseille Immunopole, and “mAbs” for monoclonal antibodies).

It aims to bridge the gap between industry and academia by accelerating the development of novel monoclonal antibodies for new targets.

MI-mAbs is based in the Parc Scientifique et Technologie de Luminy.

It’s a stone’s throw from the Centre d’Immunologie de Marseille-Luminy (CIML), which this year celebrated its 40th anniversary (1976-2016).

Panoramic view from CIML

Panoramic view from CIML

Luminy is also the home to several companies focused on immuno-oncology, including Innate Pharma and HalioDx. Marseille has the ambition to become a world leader in the development of immune-based therapies

MI-mAbs is funded by a €19M award from the French Government, as part of their Investissments d’avenir/Investments for the Future program.

The Scientific Director of MI-mAbs is Professor François Romagné. He’s a co-founder of Innate Pharma and for 14 years was the company’s Chief Scientific Officer (CSO). He’s one of the inventors of lirilumab and monalizumab, both of which are in phase 2 clinical trials.

mi-mabs-pr-francois-romagne

Professor Romagné kindly spoke to BSB about MI-mAbs and how it plans to accelerate innovation and develop new drug candidates for the treatment of cancer or inflammatory disease.

For our French speaking audience, here is a brief excerpt from the interview with Pr. Romagné, where he introduces himself and MI-mAbs.

It’s an incredible time for immunologists like Prof Romagné, where the clinical results we are seeing with new cancer immunotherapies have validated a lifetime of work.

Subscribers can login to read more or you can purchase access via the Blue Button below.

While in Marseille for the scientific meeting to celebrate the 40th anniversary of the Centre d’Immunologie de Marseille-Luminy (CIML), I had the pleasure to interview Hervé Brailly PhD, the CEO of Innate Pharma, a leading biotech company in the Marseille Immunopôle.

dr-herve-brailly-innate-pharma-ceo

Innate Pharma (@InnatePharma) was founded in 1999 by six immunologists: Hervé Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié and Francois Romagné.

Yesterday’s blog post on “Why Target the Innate Immune System? An interview with Eric Vivier” sets the scene for today’s post.

Innate Pharma, as the name suggests, has pioneered targeting the innate immune system. The company has leveraged the research undertaken at CIML by Professor Vivier and others in the field of innate immunity.

Innate is leading the way in immuno-oncology by targeting checkpoint receptors on natural killer (NK) cells. In 2011 Innate signed a licensing deal with Bristol-Myers Squibb for the development and potential commercialization of lirilumab.

In a recent financial report (link to Sept 8 press release) the company announced that several clinical trials would read-out in the forthcoming months.

Without disclosing any material non-public information, Dr Brailly kindly spoke with BSB and talked about his vision for Innate, what data readouts we are expecting, and the inflexion point the company is now at.

Subscribers can login to read more or you can purchase access below.

Marseille – When it comes to biotech clusters for immunotherapy, Marseille, the second city of France, has to be right up there along with Boston, San Francisco in the United States and the “Golden Triangle” of Oxford, Cambridge and London in the UK.

ciml40I’m here in Marseille thanks to an invitation from Professor Eric Vivier to attend the 2-day scientific conference that the Centre d’Immunologie de Marseille-Luminy (CIML) have organized as part of their fortieth anniversary celebrations (1976-2016). It starts today (Twitter #CIML40).

Surrounding CIML in the picturesque national park (Parc National des Calanques), just outside the city, are innovative biotech companies focused on immunology and cancer immunotherapy. The combination of companies, research institutes and academic hospitals in the region has created the Marseille Immunopôle (@Immunopole). The area should already be on your radar if you are following the field.

haliodx

Yesterday, I visited HalioDx (@HalioDx), a start-up company a stone’s throw from CIML. It was founded in 2015 to commercialize Immunoscore, a novel biomarker in colon cancer that can be used to stage patients based on their immune response.

Vincent Fert CEO HalioDx

Vincent Fert, CEO of HalioDx

We’ve been following the work of Dr Jérôme Galon on the blog for some time (see posts from European Cancer Congress 2015 and ASCO 2016), so it was a pleasure to talk to Vincent Fert, CEO (pictured right) and co-founder of HalioDx, about his plans to commercialize Immunoscore in Europe and the United States.

If you want to know more about the science behind Immunoscore, do listen to the recent Novel Targets Podcast (@TargetsPodcast) interview with Dr Galon, where he talks about the data he presented at ASCO 2016 (link to Episode 13: Immunotherapy or Bust).

The field of cancer immunotherapy is making rapid progress. It is already reaching the point where — in order to optimize the chance of a durable response — doctors need to know what a patient’s underlying immune response to cancer is, in order to direct therapy.

Vincent Fert and HalioDx are leading the way with the commercialization of a new diagnostic approach for colon cancer based on a patient’s immune profile. He kindly spoke with BSB about his plans for the company and making Immunoscore available in the US and Europe.

haliodx-marseille-luminy

This is the first post in a mini-series from the Marseille Immunopôle.

Subscribers can login to learn more about this approach or you can purchase access below.

error: Content is protected !!